Готові списки джерел за темами / Diagnostic and prognostic marker

Добірка наукової літератури з теми "Diagnostic and prognostic marker"

Автор: Grafiati
Опубліковано: 14 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Diagnostic and prognostic marker".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Diagnostic and prognostic marker"

1

E. A. R., Engku Nur Syafirah, Ahmad Adebayo Irekeola, and Chan Yean Yean. "Diagnostic and Prognostic Indications of Nasopharyngeal Carcinoma." Diagnostics 10, no. 9 (August 19, 2020): 611. http://dx.doi.org/10.3390/diagnostics10090611.

Повний текст джерела
Анотація:
Nasopharyngeal carcinoma (NPC) is a disease that is highly associated with the latent infection of Epstein–Barr virus. The absence of obvious clinical signs at the early stage of the disease has made early diagnosis practically impossible, thereby promoting the establishment and progression of the disease. To enhance the stride for a reliable and less invasive tool for the diagnosis and prognosis of NPC, we synopsize biomarkers belonging to the two most implicated biological domains (oncogenes and tumor suppressors) in NPC disease. Since no single biomarker is sufficient for diagnosis and prognosis, coupled with the fact that the known established methods such as methylation-specific polymerase chain reaction (PCR), multiplex methylation-specific PCR, microarray assays, etc., can only accommodate a few biomarkers, we propose a 10-biomarker panel (KIT, LMP1, PIKC3A, miR-141, and miR-18a/b (oncogenic) and p16, RASSF1A, DAP-kinase, miR-9, and miR-26a (tumor suppressors)) based on their diagnostic and prognostic values. This marker set could be explored in a multilevel or single unified assay for the diagnosis and prognosis of NPC. If carefully harnessed and standardized, it is hoped that the proposed marker set would help transform the diagnostic and prognostic realm of NPC, and ultimately, help prevent the life-threatening late-stage NPC disease.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Alieva, A. M., A. V. Sozykin, N. V. Teplova, E. V. Reznik, D. V. Izimarieva, N. A. Novikova, I. V. Lozovsky, Е. E. Averin, R. K. Valiev, and I. G. Nikitin. "Tenascin-C as a cardiovascular marker." Russian Journal of Cardiology 27, no. 8 (September 3, 2022): 5150. http://dx.doi.org/10.15829/1560-4071-2022-5150.

Повний текст джерела
Анотація:
Novel biological markers, such as fibrosis marker galectin-3, peptide hormone adrenomedullin, soluble ST2, chemokine CX3CL1, surrogate marker of vasopressin, and others, are every year one step closer to being introduced into health practice. Over the past decades, significant progress has been made in the study of cardiovascular biomarkers. A key moment was the introduction of deter mining the concentration of natriuretic peptides used as markers for the diagnostic and prognostic evaluation of patients with heart failure. Currently, in order to search for novel markers for early diagnosis and risk stratification, studies have been conducted on the analysis of promising inflammatory marker tenascin-C (TNC) in cardiovascular patients. Data have been obtained that allow us to consider TNC as a tool for risk stratification and assessment of cardiovascular disease prognosis. The combination of TNC with other biological markers, in particular brain natriuretic peptide, may improve prognostic power. Nevertheless, serial testing to assess the prognosis and effectiveness of ongoing treatment, including in the conditions of a multimarker model, requires further research.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

ZENG, XIAOJUN, and HUALIN TAO. "Diagnostic and prognostic serum marker of cholangiocarcinoma (Review)." Oncology Letters 9, no. 1 (November 10, 2014): 3–8. http://dx.doi.org/10.3892/ol.2014.2696.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Pileri, Alessandro, Martina Cavicchi, Clara Bertuzzi, Simona Righi, Corrado Zengarini, Elena Sabattini, Giovanna Roncador, and Claudio Agostinelli. "TOX Expression in Mycosis Fungoides and Sezary Syndrome." Diagnostics 12, no. 7 (June 29, 2022): 1582. http://dx.doi.org/10.3390/diagnostics12071582.

Повний текст джерела
Анотація:
Mycosis fungoides (MF) and Sezary syndrome (SS) are the two most common type of cutaneous T-cell lymphoma (CTCL). Currently, no markers can be clearly related to prognosis or to differential diagnosis between early stages and inflammatory benign diseases (IBD). The thymocyte selection-associated high mobility group box factor (TOX), has been proposed as a possible marker in differential diagnosis between early CTCL stages and IBD. Recently TOX has been related to prognosis. We aimed to investigate whether TOX may be a diagnostic or prognostic marker. MF and SS biopsies between 2010 and 2020 were retrieved. New tissues slides were stained with an anti-TOX antibody, (Clone NAN448B). On each slide, 5 fields were examined at high magnification (400×), to evaluate the percentage of marker-positivity in a quantitative way. Thirty-six patients (12 females and 24 males) and 48 biopsies were collected. Nine patients had multiple biopsies. TOX expression in MF/SS cases showed an increase from early to advanced phases. TOX was not regarded as a prognostic marker due to the absence of significant changes by comparing early MF cases with reactive conditions. TOX statistical significance increased in patients alive with disease and in those dead of disease (p = 0.013 and = 0.0005, respectively) as compared with patients in complete remission. Our results show that TOX should be regarded more as a prognostic than a diagnostic marker.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Mazur, O. H., O. S. Yablon, and O. S. Rubina. "Alpha-fetoprotein as a biochemical diagnostic and prognostic marker for prolonged jaundice in newborns." Ukrainian Biochemical Journal 91, no. 5 (September 13, 2019): 63–69. http://dx.doi.org/10.15407/ubj91.05.063.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Metovic, Jasna, Luisella Righi, Luisa Delsedime, Marco Volante, and Mauro Papotti. "Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors." Acta Cytologica 64, no. 1-2 (March 15, 2019): 16–29. http://dx.doi.org/10.1159/000496030.

Повний текст джерела
Анотація:
Pulmonary cytology is a challenging diagnostic tool, and it is usually evaluated considering medical history and radiological findings in order to reach an accurate diagnosis. Since the majority of lung cancer patients have an advanced stage at diagnosis, a cytological specimen is frequently the only material available for diagnosis and further prognostic/predictive marker determination. Several types of specimens can be obtained from the respiratory system (including sputum, bronchoalveolar lavage, bronchial brushing, fine needle aspiration, and pleural fluid) with different technical preclinical management protocols and different diagnostic yields. Immunocytochemistry (ICC) has a pivotal role in the determination of diagnostic, prognostic, and predictive markers. Therefore, limited cytology samples are to be used with a cell-sparing approach, to allow both diagnostic ICC evaluation as well as predictive marker assessment by ICC or specific molecular assays. In this review, we describe the most common ICC markers used for the diagnosis and prognostic/predictive characterization of thoracic tumors in different cytological specimens.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Khan, Azhar Ali, Reeta Singh, and Pavan Kumar Singh. "Diagnostic and prognostic significance of procalcitonin in septicemia." International Journal of Advances in Medicine 4, no. 3 (May 23, 2017): 630. http://dx.doi.org/10.18203/2349-3933.ijam20171463.

Повний текст джерела
Анотація:
Background: Sepsis is a major cause of morbidity and mortality. Early diagnosis and treatment with adequate antimicrobial therapy are essential for successful treatment. Despite the use of available treatment modalities mortality in sepsis remains high, often due to delayed diagnosis and treatment.Methods: A total of 60 patients were enrolled from Nehru Hospital, B.R.D. Medical College, Gorakhpur during the study period July 2013 to July 2014. All the patients were subjected to detailed clinical examination and investigations. Patient’s clinical profile, progression of disease and outcome were recorded. PCT and various other relevant factors were measured in all study subjects. The study was designed to assess the levels of serum PCT in patients with septicemia and to see whether serum PCT level correlates with severity of septicemia and survival outcome.Results: Procalcitonin is a useful marker for severity of infection. High procalcitonin level is highly specific for infection. Low procalcitonin level cannot be used safely to exclude the presence of infection. Higher level of serum procalcitonin predicts mortality better than other parameters available.Conclusions: From present study we can conclude that although sepsis is mainly a clinical diagnosis and its severity can be assessed by scores like APACHE II, but serum procalcitonin is a good marker for the assessing severity of the sepsis. Serum procalcitonin can aid in early diagnosis as it appears in blood earlier than other markers.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Pastare, Daina, Mohamed Ridha Bennour, Elīna Polunosika, and Guntis Karelis. "Biomarkers of Multiple Sclerosis." Open Immunology Journal 9, no. 1 (December 20, 2019): 1–13. http://dx.doi.org/10.2174/1874226201909010001.

Повний текст джерела
Анотація:
The search for an ideal multiple sclerosis biomarker with good diagnostic value, prognostic reference and an impact on clinical outcome has yet to be realized and is still ongoing. The aim of this review is to establish an overview of the frequent biomarkers for multiple sclerosis that exist to date. The review summarizes the results obtained from electronic databases, as well as thorough manual searches. In this review the sources and methods of biomarkers extraction are described; in addition to the description of each biomarker, determination of the prognostic, diagnostic, disease monitoring and treatment response values besides clinical impact they might possess. We divided the biomarkers into three categories according to the achievement method: laboratory markers, genetic-immunogenetic markers and imaging markers. We have found two biomarkers at the time being considered the gold standard for MS diagnostics. Unfortunately, there does not exist a single solitary marker being able to present reliable diagnostic value, prognostic value, high sensitivity and specificity as well as clinical impact. We need more studies to find the best biomarker for MS.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Katan, Mira, Beat Müller, and Mirjam Christ-Crain. "Copeptin: a new and promising diagnostic and prognostic marker." Critical Care 12, no. 2 (2008): 117. http://dx.doi.org/10.1186/cc6799.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Alieva, A. M., E. V. Reznik, T. V. Pinchuk, R. A. Arakelyan, R. K. Valiev, A. M. Rakhaev, A. S. Tikhomirova, and I. G. Nikitin. "Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure." Russian Archives of Internal Medicine 13, no. 1 (January 25, 2023): 14–23. http://dx.doi.org/10.20514/2226-6704-2023-13-1-14-23.

Повний текст джерела
Анотація:
Heart failure is an important medical, social and economic problem around the world. In recent years, a number of diagnostic and prognostic biological markers of blood in cardiovascular diseases have been studied. Identification of new biological markers, analysis of their pathophysiological aspects and changes in concentration under the influence of various treatment options, allow us to understand many pathogenetic features of the development and course of heart failure. In recent decades, natriuretic peptides have been introduced into clinical practice, which are widely used as reliable markers for diagnostic and prognostic assessment. Growth differentiation factor-15 is a cytokine belonging to the family of transforming growth factors, the activity of which is significantly increased under stress and inflammation. In patients with chronic heart failure, the concentration of this marker is associated with an increased risk of overall mortality and adverse cardiovascular events; in patients with heart failure with preserved left ventricular ejection fraction, the use of the marker showed prognostic and diagnostic significance. Data from the Framingham Heart Study showed that growth differentiation factor-15 was the only marker in multivariate analysis that showed a statistically significant association with all adverse cardiovascular events. Eight studies showed that overexpression of growth differentiation factor-15 was associated with an increased risk of mortality in patients with heart failure. It was shown that growth differentiation factor-15 as a prognostic marker in patients with acute heart failure is not inferior to the brain natriuretic peptide precursor. To confirm the value of this marker in blood in patients with heart failure, it is necessary to conduct extensive prospective randomized clinical trials.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Diagnostic and prognostic marker"

1

Alegre, Melissa Marie. "Thymidine Kinase 1: Diagnostic and Prognostic Significance in Malignancy." BYU ScholarsArchive, 2013. https://scholarsarchive.byu.edu/etd/4049.

Повний текст джерела
Анотація:
Thymidine kinase 1 (TK1) is a cancer biomarker which has diagnostic and prognostic potential in a variety of malignancies. TK1 is significantly elevated in the serum and tumor tissue of most malignancies. This increase in TK1 can be detected in the very early stages of malignancy, including in pre-malignant disease with an increased risk for progression. Several studies have demonstrated that elevated TK1 is found in serum months before any clinical symptoms of malignancy. It has also been demonstrated that TK1 is elevated months before clinical recurrence of malignancy. This work first sought to demonstrate the early nature of TK1 expression in breast tumor tissue and pre-malignant tissue. We found that TK1 is elevated in breast hyperplasia tissue and breast carcinoma tissue. In this study we also identified some cases of ‘normal’ tumor margins (considered normal by current pathological standards) which also had elevated TK1 expression. Conversely, true normal breast tissue from noncancerous individuals had no reported elevation in TK1 expression. This study illustrated that TK1 is elevated in pre-malignant breast hyperplasia tissue, as well as some 'normal' tumor margins. TK1 expression was significantly elevated in lung, prostate, colon, esophagus, stomach, liver, and kidney tissues. This work further investigated TK1 expression in a variety of malignant tissue including the two leading causes of cancer mortality in men: lung and prostate cancer. In our study, TK1 was significantly elevated in lung and prostate cancer but not significantly elevated in prostate hyperplasia tissue. TK1 expression also increased with increasing grade in prostate carcinoma tissue. Overall, this work demonstrated that TK1 is a good universal marker of malignancy and is elevated in early cancer development. Despite the potential for TK1 as both a screening and monitoring treatment tool, there have been significant challenges associated with developing a clinically relevant method of TK1 detection. This work proposes one clinically relevant method of detection, namely a TK1 ELISA. Using preoperable lung cancer patients and normal controls, we developed a sensitive and specific ELISA which shows highly statistically significant differences in serum TK1 levels between stage 1 and stage 2 lung cancer compared with normal controls. In fact, this TK1 ELISA is more sensitive and accurate than the traditional TK radioassay, which was unable to detect differences in TK1 between early stage lung cancer and normal patients. Although elevated TK1 is not lung cancer specific, we reported significantly elevated TK1 levels in lung cancer sputum. Screening of sputum and serum for TK1 may be one method for the early detection of lung cancer. Overall, we report TK1 has promising diagnostic potential in a variety of malignancies. We also propose one sensitive and specific method to detect TK1 levels which may easily be adapted to meet current clinical applications. We hope this work will help propel TK1 forward into clinical view in the coming years.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

MEGHA, T., A. NERI, S. CARUSO, M. ONORATI, F. ROVIELLO, P. TOSI, and VALERIA MALAGNINO. "Traditional and new diagnostic and prognostic markers in breast cancer." Doctoral thesis, Università di Siena, 2017. http://hdl.handle.net/11365/1012970.

Повний текст джерела
Анотація:
Despite the constant progress on the understanding of the molecular bases of cancer, there is still the need to identify novel prognostic and predictive markers aimed at improving diagnosis and, at the same time, designing a more targeted therapeutic approach. For this to be achieved, we have to take into consideration the biological heterogeneity of each tumor that explains different responses to standard therapies harbored by different patients within the same tumor stage and histological type. Such a combined approach does not apply to improving classification and prognosis of breast cancer only, but it is widely applicable to a better understanding and treatment of all cancers. Nevertheless, it is also crucial to bare in mind that cancer is a genetic disease and molecular analyses aimed at unravelling genetic make-up of tumors are of extreme importance. However, the contribution of the environment in the development of a neoplastic disease should not be ignored, as this would also provide useful insights for cancer prevention. Exposure to harmful substances (i.e. X-rays, UV-light, carcinogens just to list some examples) and to pathogens which might be endemic in some areas could also contribute to triggering genetic alterations whose accumulation may result in malignant transformation, and should not be ignored when trying to understand the etiology of certain tumors. The aim of this thesis is to provide evidence of how novel genetic markers may contribute to a better classification and diagnosis of cancer, using as examples studies conducted on breast cancer and lymphoma. Also, reactivation of the Epstein-Barr virus due to exposure of unfavorable environmental conditions is provided in another study, to highlight the tremendous importance of the environment in the development of cancer, which is too often dismissed in both the anamnesis of cancer patients and in research studies.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

BARONE, ELISA. "Overexpressed genes in malignant pleural mesothelioma: possible role in tumorigenesis and evaluation of their use as a prognostic marker." Doctoral thesis, Università di Siena, 2017. http://hdl.handle.net/11365/1005849.

Повний текст джерела
Анотація:
Malignant Pleural Mesothelioma (MPM) is a very aggressive cancer poorly responsive to current therapies. The prognosis is very poor as the development of MPM leads to a median survival of less than one year from the time of diagnosis (Bertino et al. 2009). Moreover, the rapidly growing nature of this cancer, the non-specific onset of symptoms and the lack of an accurate biomarker do not lead to a sufficiently early diagnosis for a radical treatment of the disease. Thus, the identification of novel diagnostic and prognostic biomarkers and therapeutic targets is needed. The knowledge of the genes involved in the triggering/progression of MPM is still limited. In recent years a number of aberrantly expressed genes were suggested, but with a poor consistency among studies. To identify the relevant genes potentially involved in MPM, recently, our group carried out an extensive literature review focused on transcriptome studies whose results were intersected with those from a data mining approach (Melaiu et al. 2012). The results underwent to validation on MPM tissues and cell lines (Melaiu et al. 2015). The study led to the identification of a group of 21 deregulated genes in MPM. Among the 21 genes identified we focused our attention on those up-regulated in MPM tissues and at least in one MPM cell line (i.e. THBS2, CCNO, CFB, TIMP3, SULF1, PDGFRB, ASS1, SOD1, RAN, CDH11, EIF4G1). In addition, we made an extensive literature search to identify the most promising novel diagnostic and therapeutic target for MPM and we undertook the study of IMP3 (Hanley et al.2008; Ikeda et al. 2010; Ikeda et al. 2011; Shi et al.2011; Lee et al. 2013; Okazaki et al. 2013; Minato et a. 2014) , MCT4 (Mogi et al. 2013), MCT1 (Mogi et al. 2013), BSG (Pinheiro et al. 2012) and CAIX (Ramsey et al. 2012; Capkova et al. 2014). In order to investigate the role of these genes in the carcinogenesis of MPM we performed a phenotypic screening of five MPM cell lines (Mero14, Mero25, IstMes2, NCI-H28, REN) and one non-malignant mesothelial cell line (Met5A) following gene-silencing. We analysed the changes in the proliferation rate, in the caspase3-7 activity, in the migration ability, in the colony formation ability, in the level of senescence and in the cell cycle after transient siRNA transfections. The RNAi screening highlighted a role in MPM malignant phenotype for ASS1, CDH11, EIF4G1, IMP3, MCT4, PDGFRB, RAN, SOD1, SULF1, THBS2, TIMP3. Moreover, we evaluated the potential prognostic role of THBS2, CDH11, ITGA4, MCT4, MCT1, BSG and CAIX through a tissue microarray (TMA) immunohistochemistry on a series of 135 MPM samples. None of the target analysed showed a statistical significant association, after multiple correction, between protein expression and the overall survival. The weak staining of THBS2 and the negative staining of MCT4 on six normal pleura samples compared to MPM tissues prompted us to further investigate on protein expression levels: we increased the analysis of protein expression to 15 normal pleura samples. These results highlights the role of a group of genes, overexpressed in MPM, in the carcinogenetic process suggesting potential novel therapeutic approaches for the treatment of MPM.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Al-Khalili, Faris. "Coronary heart disease in women : diagnostic and prognostic markers /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4092-4/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Abou, Farha Khalid Mohamed Mohamed. "Diagnostic and prognostic value of laminin as a biochemical and a histological marker in human bladder carcinoma." Maastricht : Maastricht : Universitaire Pers Maastricht ; University Library, Maastricht University [Host], 1992. http://arno.unimaas.nl/show.cgi?fid=6506.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Carpio, Ricardo, Juan Zapata, Eberhard Spanuth, and Georg Hess. "Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department." Elsevier B.V, 2015. http://hdl.handle.net/10757/576944.

Повний текст джерела
Анотація:
Presepsin (PSEP) is released during infectious diseases and can be detected in the blood. PSEP has shown promising results as sepsis marker. We examined the diagnostic and prognostic validity of PSEP in patients suspicious of sepsis on admission in the emergency department (ED). Methods One hundred twenty three patients with signs of SIRS and/or sepsis and 123 healthy individuals were enrolled. PSEP was determined on admission, after 8, 24 and 72 h. Results Mean PSEP concentrations of the control group and the patient group were 130 and 1945 pg/ml. PSEP differed between SIRS, sepsis, severe sepsis and septic shock and showed strong association with 30-day mortality ranging from 10.3% in the 1st to 32.1% in the 4th quartile. The ROC curve analyses revealed an AUC value of 0.743. Combined assessment of PSEP and MEDS score increased the AUC up to 0.878 demonstrating the close relationship with outcome. Based on the PSEP values in the different severity degrees, decision thresholds for risk stratification were established. The course of PSEP during the first 72 h was associated with effectiveness of treatment and outcome. Conclusions PSEP allowed outcome prediction already on admission to a similar degree as the clinical scores MEDS and APACHE II. Combination of PSEP with MEDS score improved the discriminatory power for outcome prediction.
Our study has been supported by Mitsubishi Chemical Europe through providing the PSEP reagents free of charge. Dr. Carpio has received speaker honoraria from Mitsubishi Chemical Europe. DIAneering – Diagnostics Engineering & Research consulted to Axis Shield Diagnostics, Mitsubishi Chemical Europe, Radiometer, Roche Diagnostics, Shanghai Kehua Bio-engineering. No potential conflict of interest to this paper was reported
Peer review
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Danner, Maria [Verfasser], and Elisabeth [Akademischer Betreuer] Pollerberg. "Marker-free T cell phenotyping - towards a label-free diagnostic and prognostic platform / Maria Danner ; Betreuer: Elisabeth Pollerberg." Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1178008258/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Danner, Maria [Verfasser], and G. Elizabeth [Akademischer Betreuer] Pollerberg. "Marker-free T cell phenotyping - towards a label-free diagnostic and prognostic platform / Maria Danner ; Betreuer: Elisabeth Pollerberg." Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://nbn-resolving.de/urn:nbn:de:bsz:16-heidok-222400.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Gaigneaux, Anthoula. "Determination of diagnostic and prognostic markers in varied tumoral pathologies by ATR-FTIR spectroscopy." Doctoral thesis, Universite Libre de Bruxelles, 2004. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/211150.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Nicol, Lisa Margaret. "Diagnostic and prognostic value of current phenotyping methods and novel molecular markers in idiopathic pulmonary fibrosis." Thesis, University of Edinburgh, 2018. http://hdl.handle.net/1842/33098.

Повний текст джерела
Анотація:
Background Idiopathic pulmonary fibrosis (IPF) is a devastating form of chronic lung injury of unknown aetiology characterised by progressive lung scarring. A diagnosis of definite IPF requires High Resolution Computed Tomography (HRCT) appearances indicative of usual interstitial pneumonia (UIP), or in patients with 'possible UIP' CT appearances, histological confirmation of UIP. However the proportion of such patients that undergo SLB varies, perhaps due to a perception of risk of biopsy and additive diagnostic value of biopsy in individual patients. We hypothesised that an underlying UIP pathological pattern may result in increased risk of death and aimed to explore this by comparing the risk of SLB in suspected idiopathic interstitial pneumonia, stratified according to HRCT appearance. Additionally we sought to determine the positive-predictive value of biopsy to diagnose IPF in patients with 'possible UIP HRCT' in our population. In patients with possible UIP who are not biopsied, the clinical value of bronchoalveolar lavage (BAL) is uncertain. We aimed to prospectively study the diagnostic and prognostic value of BAL differential cell count (DCC) in suspected IPF and determine the feasibility of repeat BAL and the relationship between DCC and disease progression in two successive BALs. We hypothesised that BAL DCC between definite and possible IPF was different and that baseline DCC and change in BAL DCC predicted disease progression. Alveolar macrophages (AMs) are an integral part of the lung's reparative mechanism following injury, however in IPF they contribute to pathogenesis by releasing pro-fibrotic mediators promoting fibroblast proliferation and collagen deposition. Expansion of novel subpopulations of pulmonary monocyte-like cells (PMLCs) has been reported in inflammatory lung disease. We hypothesised that a distinct AM polarisation phenotype would be associated with disease progression. We aimed to perform detailed phenotyping of AM and PMLCs in BAL in IPF patients. Several prognostic scoring systems and biomarkers have been described to predict disease progression in IPF but most were derived from clinical trial patients or tertiary referral centres and none have been validated in separate cohorts. We aimed to identify a predictive tool for disease progression utilising physiological, HRCT and serum biomarkers in a unique population of incident treatment naïve IPF patients. Methods Between 01/01/07 and 31/12/13, 611 consecutive incident patients with suspected idiopathic interstitial pneumonia (IIP) presented to the Edinburgh lung fibrosis clinic. Of these patients 222 underwent video-assisted thoracoscopic lung biopsy and histological pattern was determined according to ATS/ERS criteria. Post-operative mortality and complication rates were examined. Fewer than 2% received IPF-directed therapy and less than 1% of the cohort were lost to follow-up. Disease progression was defined as death or ≥10% decline in VC within 12 months of BAL. Cells were obtained by BAL and a panel of monoclonal antibodies; CD14, CD16, CD206, CD71, CD163, CD3, CD4, CD8 and HLA-DR were used to quantify and selectively characterise AMs, resident PMLCs, inducible PMLCs, neutrophils and CD4+/CD8+ T-cells using flow cytometry. Classical, intermediate and non-classical monocyte subsets were also quantified in peripheral blood. Potential biomarkers (n=16) were pre-selected from either previously published studies of IPF biomarkers or our hypothesis-driven profiling. Linear logistic regression was used on each predictor separately to assess its importance in terms of p-value of the associated weight, and the top two variables were used to learn a decision tree. Results Based on the 2011 ATS/ERS criteria, 87 patients were categorised as 'definite UIP', of whom 3 underwent SLB for clinical indications. IPF was confirmed in all 3 patients based on 2013 ATS/ERS/JRS/ALAT diagnostic criteria. 222 patients were diagnosed with 'possible UIP'; 55 underwent SLB, IPF was subsequently diagnosed in 37 patients, 4 were diagnosed with 'probable IPF' and 14 were considered 'not IPF'. In this group, 30 patients were aged 65 years or over and 25/30 (83%) had UIP on biopsy. 306 patients had HRCTs deemed 'inconsistent with UIP', SLB was performed in 168 patients. Post6 operative 30-day mortality was 2.2% overall, and 7.3% in the 'possible UIP' HRCT group. Patients with 'definite IPF' based on HRCT and SLB appearances had significantly better outcomes than patients with 'definite UIP' on HRCT alone (P=0.008, HR 0.44 (95% CI 0.240 to 0.812)). BAL DCC was not different between definite and possible UIP groups, but there were significant differences with the inconsistent with UIP group. In the 12 months following BAL, 33.3% (n=7/21) of patients in the definite UIP group and 29.5% (n=18/61) in the possible UIP group had progressed. There were no significant differences in BAL DCC between progressor and non-progressor groups. Mortality in patients with suspected IPF and a BAL DCC consistent with IPF was no different to those with a DCC inconsistent with IPF (P=0.425, HR 1.590 (95% CI 0.502 to 4.967)). There was no difference in disease progression in either group (P=0.885, HR 1.081 (95% CI 0.376 to 3.106)). There was no statistically significant difference in BAL DCC at 0 and 12 months in either group. There was no significant change in DCC between 0 and 12 month BALs between progressors and non-progressors. Repeat BAL was well tolerated in almost all patients. There was 1 death within 1 month of a first BAL and 1 death within 1 month of a second BAL; both were considered 'probably procedure-related'. AM CD163 and CD71 (transferrin receptor) expression were significantly different between groups (P < 0.0001), with significant increases in the IPF group vs non fibrotic ILD (P < 0.0001) and controls (P < 0.0001 and P < 0.001 respectively). CD71 expression was also significantly increased in the IPF progressor vs non-progressor group (P < 0.0001) and patients with high CD71 expression had significantly poorer survival than the CD71low group (P=0.040, median survival 40.5 and 75.6 months respectively). CD206 (mannose receptor) expression was also significantly higher in the IPF progressor vs non-progressor group (P=0.034). There were no differences in baseline BAL neutrophil, eosinophil or lymphocyte percentages between IPF progressor or non-progressor groups. The percentage of rPMLCs was significantly increased in BAL fluid cells of IPF patients compared to those with non-fibrotic ILD (P < 0.0001) and healthy controls (P < 0.05). Baseline rPMLC percentage was significantly higher in IPF progressors vs IPF non-progressors (P=0.011). Baseline BAL iPMLC:rPMLC ratio was also significantly different between IPF progressor and non-progressor groups (P=0.011). Disease progression was confidently predicted by a combination of clinical and serological variables. In our cohort we identified a predictive tool based on two key parameters, one a measure of lung function and one a single serum biomarker. Both parameters were entered into a decision tree, and when applied to our cohort yielded a sensitivity of 86.4%, specificity of 92.3%, positive predictive value of 90.5% and negative predictive value of 88.9%. We also applied previously reported predictive tools such as the GAP Index, du Bois score and CPI Index to the Edinburgh IPF cohort. Conclusions SLB can be of value in the diagnosis of ILD, however perhaps due to the perceived risks associated with the procedure, only a small percentage of patients undergo SLB despite recommendations that patients have histological confirmation of the diagnosis. Advanced age is a strong predictor for IPF, and in our cohort 83% of patients aged over 65 years with 'possible UIP' HRCT appearances, had UIP on biopsy. BAL and repeat BAL in IPF is feasible and safe (< 1.5% mortality). Of those that underwent repeat BAL, disease progression was not associated with a change in DCC. However, 22% of lavaged patients died or were deemed too frail to undergo a second procedure at 12 months. These data emphasise the importance of BAL in identifying a novel human AM polarisation phenotype in IPF. Our data suggests there is a distinct relationship between AM subtypes, cell-surface expression markers, PMLC subpopulations and disease progression in IPF. This may be utilised to investigate new targets for future therapeutic strategies.
Disease progression in IPF can be predicted by a combination of clinical variables and serum biomarker profiling. We have identified a unique prediction model, when applied to our locally referred, incident, treatment naïve cohort can confidently predict disease progression in IPF. IPF is a heterogeneous disease and there is a definite clinical need to identify 'personalised' prognostic biomarkers which may in turn lead to novel targets and the advent of personalised medicines.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Diagnostic and prognostic marker"

1

Diagnostic and prognostic biomarkers and therapeutic targets in melanoma. Totowa, N.J: Humana, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Russo, Antonio, Stefano Iacobelli, and Juan Iovanna, eds. Diagnostic, Prognostic and Therapeutic Value of Gene Signatures. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-61779-358-5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Nieto, Mark E. Naval aviation aging wiring: Prognostic and diagnostic solutions. Monterey, Calif: Naval Postgraduate School, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Hughes, Mark D. Point-of-care testing: Status and prognosis. Waltham, MA: Decision Resources, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Murphy, Michael J., ed. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-60761-433-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

K, Pantel, ed. Minimal residual epithelial cancer: Diagnostic approaches and prognostic relevance. Stuttgart: Gustav Fischer Verlag, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Jemeï, Samir. Hybridization, Diagnostic and Prognostic of Proton Exchange Membrane Fuel Cells. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781119563426.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

CNS cancer: Models, markers, prognostic factors, targets, and therapeutic approaches. Central nervous system cancer: Humana Press, 2009.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

The clinical marker hCG. New York: Praeger, 1987.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Sevelius, Ewa. Chronic liver disease in the dog: A demographic, aetiologic, diagnostic and prognostic study. Uppsala: Sveriges Lantbruksuniversitet, 1995.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Diagnostic and prognostic marker"

1

Nosrati, Mehdi, and Mohammed Kashani-Sabet. "Immunohistochemical Diagnostic and Prognostic Markers for Melanoma." In Methods in Molecular Biology, 259–73. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-727-3_14.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Joerger, Markus, and Jens Huober. "Diagnostic and Prognostic Use of Bone Turnover Markers." In Prevention of Bone Metastases, 197–223. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-21892-7_10.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Xing, Mingzhao. "Diagnostic and Prognostic Molecular Markers in Thyroid Cancer." In Thyroid Cancer, 281–92. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3314-3_22.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Domínguez-Muñoz, J. E., and P. Malfertheiner. "Biochemical Markers in the Early Prognostic Evaluation of Acute Pancreatitis." In Diagnostic Procedures in Pancreatic Disease, 109–17. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60580-2_14.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Levine, Danielle, and David E. Fisher. "Current Status of Diagnostic and Prognostic Markers in Melanoma." In Methods in Molecular Biology, 177–97. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-727-3_11.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hafner, Christian. "Nonmelanoma Skin Cancer: Use of Epha1 Receptor as a Prognostic Marker." In Methods of Cancer Diagnosis, Therapy, and Prognosis, 333–40. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2918-8_28.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Taback, Bret, and Dave S. B. Hoon. "Microsatellite Alterations as Diagnostic and Prognostic Molecular Markers in Patients With Cancer." In Cancer Diagnostics, 395–428. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-791-8_19.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Pasquali, Sandro, Augustinus P. T. van der Ploeg, and Simone Mocellin. "Molecular Markers of Lymph Node Disease in Melanoma." In Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma, 209–26. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-60761-433-3_16.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Terry, Jefferson, and Torsten O. Nielsen. "Synovial Sarcoma: Role of TLE1 as a Diagnostic Immunohistochemical Marker." In Methods of Cancer Diagnosis, Therapy, and Prognosis, 393–403. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2918-8_32.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Adams, Jesse E. "The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery." In Cardiac Markers, 111–21. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1007/978-1-59259-385-9_6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Diagnostic and prognostic marker"

1

Zahid, Muhammad Ammar, and Abdelali Agouni. "Identification of a miRNA signature as a diagnostic and prognostic marker in renal cell carcinoma." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0109.

Повний текст джерела
Анотація:
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC). If diagnosed in later stages, ccRCC is associated with high renal cancer related morbidity and poor prognosis. Recently, microRNAs (miRNAs) have attracted interest as potential diagnostic and prognostic biomarkers due to their important role in cancer development and progression. Availability of big omics data in the cancer genome atlas (TCGA) coupled with data mining and machine learning have revolutionized the identification of robust diagnostic and prognostic signatures in different types of cancers. In this study, we have utilized the miRNA sequencing data of 516 ccRCC patients from TCGA to identify a diagnostic and prognostic signature by using a combined approach of differential expression analysis, survival analysis and machine learning. Differential expression analysis identified 30 downregulated and 20 upregulated miRNAs in the primary tumor as compared to solid tissue normal samples. Out of these 50 differentially expressed miRNAs, higher expression of 7 and lower expression of 6 miRNAs were found to be significantly associated with poor survival when analyzed using the Kaplan-Maier survival method. Pathway enrichment analyses related to the differentially expressed miRNAs revealed that fatty acid biosynthesis was the most significantly enriched KEGG pathway while proteoglycans in cancer pathway was enriched by the highest number of survival-associated miRNAs target genes. Differential expression and association with poor survival was used as a prefilter for training a support vector machine model capable of classifying tumor samples from solid tissue normal samples with an accuracy and precision of 99.23% and 98.50%, respectively. We have identified here a nine-miRNA signature in ccRCC patients that is capable of segregating tumor from normal tissue samples with high accuracy and precision. The future validation of this classification model in in a clinical cohort will support translation of these findings into clinical practice for early detection and follow-up of ccRCC.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Prina, Elena, Miquel Ferrer, Eva Polverino, Cata Cilloniz, otavio Renzani, elena Moreno, Josep Mensa, et al. "Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a1802.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Simon, Ronald, Martina Kluth, Kristine Fischer, Sarah Bonk, Claudia Hube-Magg, Doris Höflmayer, Maximilian Lennartz, et al. "Abstract 430: Prostate specific antigen (PSA) as a diagnostic and prognostic marker of prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-430.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Simon, Ronald, Martina Kluth, Kristine Fischer, Sarah Bonk, Claudia Hube-Magg, Doris Höflmayer, Maximilian Lennartz, et al. "Abstract 430: Prostate specific antigen (PSA) as a diagnostic and prognostic marker of prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-430.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Tobon-Mejia, D. A., K. Medjaher, N. Zerhouni, and G. Tripot. "Hidden Markov Models for failure diagnostic and prognostic." In 2011 Prognostics and System Health Management Conference (PHM-2011 Shenzhen). IEEE, 2011. http://dx.doi.org/10.1109/phm.2011.5939488.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Ossman, Heba E., Shreen A. El-Masry, Nour M. Abdel Aal, and Amira M. Mokhtar. "The Promising Rule of Neutrophil CD64 As an Early Diagnostic and Prognostic Marker in Neonatal Sepsis." In Selection of Abstracts From NCE 2015. American Academy of Pediatrics, 2017. http://dx.doi.org/10.1542/peds.140.1_meetingabstract.62.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Singh, Mayank, Atul Batra, Sameer Bakhshi, and Matthew Summers. "Abstract 1256: Validation of Ubiquitin specific peptidases 37 as a prognostic and diagnostic marker in osteosarcoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1256.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Singh, Mayank, Atul Batra, Sameer Bakhshi, and Matthew Summers. "Abstract 1256: Validation of Ubiquitin specific peptidases 37 as a prognostic and diagnostic marker in osteosarcoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1256.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Cofrancesco, E., E. Poliani, M. Salvatore, C. Boschetti, G. Moreo та M. Cortellaro. "ALPHA-2-ANTIPLASMIN (α2AP) IN ACUTE NONLYMPHOBLASTIC LEUKAEMIA AS A MARKER OF DISEASE ACTIVITY". У XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643205.

Повний текст джерела
Анотація:
α2AP (Coatest Antiplasmin Kit, Ortho Diagnostic Systems), antithrombin III (Atlll, Coatest Antithrombin Kit, Ortho Diagnostic Systems) and plasminogen (S2251) were assayed in 21 patients with acute nonlymphoblastic leukaemia (ANLL: 5M2 5M4 5M5) before and after chemotherapy and during bone marrow cellularity recovery. The aim of the work was to investigated disturbances of coagulation and fibrinolysis with special reference to proteases inhibitors and to evaluate the prognostic value of changes in these parameters in ANLL patients. Low α2AP levels were observed in the initial phase of the disease: Ul.5 ± 2k.79 SD in 10 DIC patients versus 6U.10 !± 20.70 SD in patients without DIC (p < 0.05). α2AP normalized only in the 11 patients who achieved haematological remission (71.63 ± 13.13 SD) and remained low in those who did not respond to chemotherapy (6l.88 ± 17.86 SD, p < 0.01). No significant modification of Atlll and plasminogen levels were observed during the course of the illness.It may be postulated that proteolytic cleavage of α2AP by granulocyte proteases contributes to the low levels of the inhibitor in ANLL, and suggested that α2AP may represent a marker of leu-kaemic disease activity. In fact the mean α2AP level of all patients at diagnosis plus those who did not respond to chemotherapy was significantly lower than that of patients in haematological remission (55.93 ± 23.13 versus 71.63 ± 13.13, p < 0.05).
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Andavolu, Radhika Gade, Catherine Stafford, Patrick Herling, Isabella Bianco, Jean-Luc Cardenas, Henry Go, Svetlana Rubakovic, and Murthy V. Andavolu. "Abstract 4775: Astrocyte elevated gene-1(AEG-1)as a potential diagnostic/prognostic marker for prostate cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4775.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Diagnostic and prognostic marker"

1

Sharma, Shvetank. SAMM50 Level as a Prognostic and/or Diagnostic Marker for Breast Cancer Development and Progression. Fort Belvoir, VA: Defense Technical Information Center, October 2011. http://dx.doi.org/10.21236/ada581657.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Keyomarsi, Khandan. Cyclin E, A Potential Prognostic Marker in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 1998. http://dx.doi.org/10.21236/ada368551.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Keyomarsi, Khandan. Cyclin E, a Potential Prognostic Marker in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 1997. http://dx.doi.org/10.21236/ada341275.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Baylin, Stephen B. Hypermethylation of AP-2Alpha as a Prognostic Marker for DCIS. Fort Belvoir, VA: Defense Technical Information Center, May 2008. http://dx.doi.org/10.21236/ada494142.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Baylin, Stephen. Hypermethylation of AP-2alpha as a Prognostic Marker for DCIS. Fort Belvoir, VA: Defense Technical Information Center, May 2006. http://dx.doi.org/10.21236/ada456138.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Cassady, C. R., Heather L. Nachtmann, Edward A. Pohl, Alejandro Mendoza, Letitia Pohl, and Nick Rew. Maintenance Decision-Making Under Prognostic and Diagnostic Uncertainty. Fort Belvoir, VA: Defense Technical Information Center, January 2005. http://dx.doi.org/10.21236/ada452058.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Serrero, Ginette. Novel Growth Factor as Prognostic Marker for Estrogen-Independence in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2003. http://dx.doi.org/10.21236/ada424094.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Agarwal, Vivek, Nancy J. Lybeck, and Binh T. Pham. Diagnostic and Prognostic Models for Generator Step-Up Transformers. Office of Scientific and Technical Information (OSTI), September 2014. http://dx.doi.org/10.2172/1166054.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Author, Not Given. STTR Topic N07-T002: Aircraft Battery Diagnostic and Prognostic System. Office of Scientific and Technical Information (OSTI), September 2008. http://dx.doi.org/10.2172/989101.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Byington, Carl S., Michael J. Roemer, Gregory J. Kacprzynski, and Thomas Galie. Prognostic Enhancements to Diagnostic Systems for Improved Condition-Based Maintenance. Fort Belvoir, VA: Defense Technical Information Center, January 2002. http://dx.doi.org/10.21236/ada408880.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Diagnostic and prognostic marker" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії